GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Liabilities-to-Assets

EV Biologics (EV Biologics) Liabilities-to-Assets : 0.28 (As of Dec. 2017)


View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. EV Biologics's Total Liabilities for the quarter that ended in Dec. 2017 was $16.72 Mil. EV Biologics's Total Assets for the quarter that ended in Dec. 2017 was $58.95 Mil. Therefore, EV Biologics's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2017 was 0.28.


EV Biologics Liabilities-to-Assets Historical Data

The historical data trend for EV Biologics's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Liabilities-to-Assets Chart

EV Biologics Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17
Liabilities-to-Assets
0.53 0.46 0.40 0.69 0.89

EV Biologics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17 Dec17
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.76 0.82 0.89 0.28

Competitive Comparison of EV Biologics's Liabilities-to-Assets

For the Biotechnology subindustry, EV Biologics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EV Biologics's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EV Biologics's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where EV Biologics's Liabilities-to-Assets falls into.



EV Biologics Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

EV Biologics's Liabilities-to-Assets Ratio for the fiscal year that ended in Jun. 2017 is calculated as:

Liabilities-to-Assets (A: Jun. 2017 )=Total Liabilities/Total Assets
=29.559/33.278
=0.89

EV Biologics's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2017 is calculated as

Liabilities-to-Assets (Q: Dec. 2017 )=Total Liabilities/Total Assets
=16.719/58.954
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EV Biologics  (OTCPK:YECO) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


EV Biologics Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of EV Biologics's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


EV Biologics (EV Biologics) Business Description

Traded in Other Exchanges
N/A
Address
1621 Central Avenue, Cheyenne, WY, USA, 82001
EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.
Executives
Daniel S Mckinney director, 10 percent owner, officer: CEO TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan director C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3

EV Biologics (EV Biologics) Headlines

From GuruFocus

EV Biologics Unveils NFT Dividend Warrant

By ACCESSWIRE ACCESSWIRE 07-26-2021

EV Biologics Launches Excyte with $100 million Valuation

By ACCESSWIRE ACCESSWIRE 08-15-2022

EV Biologics Updates on NFT Warrant Dividend Distribution

By ACCESSWIRE ACCESSWIRE 08-30-2021

EV Biologics Signs LOI with Lonza Cell & Gene Therapy

By ACCESSWIRE ACCESSWIRE 07-22-2021

EV Biologics NFT Dividend Information

By ACCESSWIRE ACCESSWIRE 08-09-2021

EV Biologics Initiates PCAOB Audit to Seek Uplift to OTCQX

By ACCESSWIRE ACCESSWIRE 11-14-2022

EV Biologics NFT Dividend Update

By ACCESSWIRE ACCESSWIRE 07-19-2021